# PeptideScanner evidence objects: Glatiramer acetate

Every published version of the records placed with Glatiramer acetate, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json. Selected public evidence only; not medical advice.

- Objects: 65
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00078338-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00078338

> PeptideScanner retained ClinicalTrials.gov record NCT00078338 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-27, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00078338-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-06-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00078338-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00078338-glatiramer-acetate-v1
- Content SHA-256: `797e0b50074751ad7c8405e531e7013a3978e97352471399884f86aeeee3506b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00078338 ([`ctg-observation-nct00078338-2018-06-27-44f2e12bc965`](#source-ctg-observation-nct00078338-2018-06-27-44f2e12bc965))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00078338 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-27, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00078338-2018-06-27-44f2e12bc965`](#source-ctg-observation-nct00078338-2018-06-27-44f2e12bc965))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00078338 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-27, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00078338-2018-06-27-44f2e12bc965`](#source-ctg-observation-nct00078338-2018-06-27-44f2e12bc965))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00078338-2018-06-27-44f2e12bc965`](#source-ctg-observation-nct00078338-2018-06-27-44f2e12bc965))

### Sources

<a id="source-ctg-observation-nct00078338-2018-06-27-44f2e12bc965"></a>
- **ClinicalTrials.gov record NCT00078338 · retained source version 2018-06-27:44f2e12bc965ed20e632170b851509eb968bebca74f0d26f53224ba69d4cc110** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00078338) (`ctg-observation-nct00078338-2018-06-27-44f2e12bc965`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00078338." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00078338-glatiramer-acetate-v1 SHA-256: 797e0b50074751ad7c8405e531e7013a3978e97352471399884f86aeeee3506b.

---

<a id="clinicaltrials-gov-nct00176592-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00176592

> PeptideScanner retained ClinicalTrials.gov record NCT00176592 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00176592-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00176592-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00176592-glatiramer-acetate-v1
- Content SHA-256: `27a5d3a2753d01310dfc61cc4d2cf1a50fbd82d7b5cc7b298e7edafc5523947d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00176592 ([`ctg-observation-nct00176592-2021-11-16-590113bfa027`](#source-ctg-observation-nct00176592-2021-11-16-590113bfa027))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00176592 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00176592-2021-11-16-590113bfa027`](#source-ctg-observation-nct00176592-2021-11-16-590113bfa027))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00176592 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00176592-2021-11-16-590113bfa027`](#source-ctg-observation-nct00176592-2021-11-16-590113bfa027))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00176592-2021-11-16-590113bfa027`](#source-ctg-observation-nct00176592-2021-11-16-590113bfa027))

### Sources

<a id="source-ctg-observation-nct00176592-2021-11-16-590113bfa027"></a>
- **ClinicalTrials.gov record NCT00176592 · retained source version 2021-11-16:590113bfa0271bfc963d707ccc4466d3ad6a3c1e12a87efbd8219cbd1ae22edc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00176592) (`ctg-observation-nct00176592-2021-11-16-590113bfa027`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00176592." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00176592-glatiramer-acetate-v1 SHA-256: 27a5d3a2753d01310dfc61cc4d2cf1a50fbd82d7b5cc7b298e7edafc5523947d.

---

<a id="clinicaltrials-gov-nct00203021-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00203021

> PeptideScanner retained ClinicalTrials.gov record NCT00203021 at 2026-11-16T17:42:50.457Z. Its registry update date was 2020-02-18, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00203021-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-02-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00203021-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00203021-glatiramer-acetate-v1
- Content SHA-256: `d5a21c0f0e29e4de6ffa2cde950a857df5f59a47686d51670029dcefcc8385e6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00203021 ([`ctg-observation-nct00203021-2020-02-18-eef28b0ec739`](#source-ctg-observation-nct00203021-2020-02-18-eef28b0ec739))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00203021 at 2026-11-16T17:42:50.457Z. Its registry update date was 2020-02-18, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00203021-2020-02-18-eef28b0ec739`](#source-ctg-observation-nct00203021-2020-02-18-eef28b0ec739))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00203021 at 2026-11-16T17:42:50.457Z. Its registry update date was 2020-02-18, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00203021-2020-02-18-eef28b0ec739`](#source-ctg-observation-nct00203021-2020-02-18-eef28b0ec739))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00203021-2020-02-18-eef28b0ec739`](#source-ctg-observation-nct00203021-2020-02-18-eef28b0ec739))

### Sources

<a id="source-ctg-observation-nct00203021-2020-02-18-eef28b0ec739"></a>
- **ClinicalTrials.gov record NCT00203021 · retained source version 2020-02-18:eef28b0ec73912ac8734300a99abe99485b61fb20ab405d1dc9ba7a0fc127605** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00203021) (`ctg-observation-nct00203021-2020-02-18-eef28b0ec739`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00203021." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00203021-glatiramer-acetate-v1 SHA-256: d5a21c0f0e29e4de6ffa2cde950a857df5f59a47686d51670029dcefcc8385e6.

---

<a id="clinicaltrials-gov-nct00211887-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00211887

> PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00211887-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-04-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00211887-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00211887-glatiramer-acetate-v1
- Content SHA-256: `d84c1c5878b1c1f31ebfa8f633704bdd529b273b06b409091b5bf1d5fce2cdef`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00211887 ([`ctg-observation-nct00211887-2014-04-03-66d0c6622814`](#source-ctg-observation-nct00211887-2014-04-03-66d0c6622814))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00211887-2014-04-03-66d0c6622814`](#source-ctg-observation-nct00211887-2014-04-03-66d0c6622814))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00211887-2014-04-03-66d0c6622814`](#source-ctg-observation-nct00211887-2014-04-03-66d0c6622814))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00211887-2014-04-03-66d0c6622814`](#source-ctg-observation-nct00211887-2014-04-03-66d0c6622814))

### Sources

<a id="source-ctg-observation-nct00211887-2014-04-03-66d0c6622814"></a>
- **ClinicalTrials.gov record NCT00211887 · retained source version 2014-04-03:66d0c66228142788beaf0050494fa80c2926e93a61fbf9bce0f452c057d021ef** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00211887) (`ctg-observation-nct00211887-2014-04-03-66d0c6622814`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00211887." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00211887-glatiramer-acetate-v1 SHA-256: d84c1c5878b1c1f31ebfa8f633704bdd529b273b06b409091b5bf1d5fce2cdef.

---

<a id="clinicaltrials-gov-nct00239993-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00239993

> PeptideScanner retained ClinicalTrials.gov record NCT00239993 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00239993-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00239993-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00239993-glatiramer-acetate-v1
- Content SHA-256: `49c74ee474a0aea0159cdc735175d48b1774847e0b0ddb7801cfb91fac360cc0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00239993 ([`ctg-observation-nct00239993-2017-02-06-f6962621bcce`](#source-ctg-observation-nct00239993-2017-02-06-f6962621bcce))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00239993 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00239993-2017-02-06-f6962621bcce`](#source-ctg-observation-nct00239993-2017-02-06-f6962621bcce))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00239993 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00239993-2017-02-06-f6962621bcce`](#source-ctg-observation-nct00239993-2017-02-06-f6962621bcce))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00239993-2017-02-06-f6962621bcce`](#source-ctg-observation-nct00239993-2017-02-06-f6962621bcce))

### Sources

<a id="source-ctg-observation-nct00239993-2017-02-06-f6962621bcce"></a>
- **ClinicalTrials.gov record NCT00239993 · retained source version 2017-02-06:f6962621bcce52f930dc732a44bee05d2a91fc1728b422f316caa3bcca671d8d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00239993) (`ctg-observation-nct00239993-2017-02-06-f6962621bcce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00239993." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00239993-glatiramer-acetate-v1 SHA-256: 49c74ee474a0aea0159cdc735175d48b1774847e0b0ddb7801cfb91fac360cc0.

---

<a id="clinicaltrials-gov-nct00337779-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00337779

> PeptideScanner retained ClinicalTrials.gov record NCT00337779 at 2026-11-16T17:42:50.457Z. Its registry update date was 2011-10-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00337779-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-10-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00337779-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00337779-glatiramer-acetate-v1
- Content SHA-256: `5a559b55bb37ea6ace69ae161fde4a4fbd6a138ee6283217648548265c8a3d1e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00337779 ([`ctg-observation-nct00337779-2011-10-10-5101942aad87`](#source-ctg-observation-nct00337779-2011-10-10-5101942aad87))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00337779 at 2026-11-16T17:42:50.457Z. Its registry update date was 2011-10-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00337779-2011-10-10-5101942aad87`](#source-ctg-observation-nct00337779-2011-10-10-5101942aad87))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00337779 at 2026-11-16T17:42:50.457Z. Its registry update date was 2011-10-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00337779-2011-10-10-5101942aad87`](#source-ctg-observation-nct00337779-2011-10-10-5101942aad87))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00337779-2011-10-10-5101942aad87`](#source-ctg-observation-nct00337779-2011-10-10-5101942aad87))

### Sources

<a id="source-ctg-observation-nct00337779-2011-10-10-5101942aad87"></a>
- **ClinicalTrials.gov record NCT00337779 · retained source version 2011-10-10:5101942aad87ab5f14c0f1e12cff2bd93e9d1ef4395a1ac8472ff996502bdc2e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00337779) (`ctg-observation-nct00337779-2011-10-10-5101942aad87`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00337779." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00337779-glatiramer-acetate-v1 SHA-256: 5a559b55bb37ea6ace69ae161fde4a4fbd6a138ee6283217648548265c8a3d1e.

---

<a id="clinicaltrials-gov-nct00451204-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00451204

> PeptideScanner retained ClinicalTrials.gov record NCT00451204 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-06-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00451204-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-06-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00451204-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00451204-glatiramer-acetate-v1
- Content SHA-256: `2341e75e5bf8b471c8cbabd975314b3113cca71dce36211d28f222a1cac3ec4a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00451204 ([`ctg-observation-nct00451204-2016-06-16-4a9caad1c155`](#source-ctg-observation-nct00451204-2016-06-16-4a9caad1c155))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00451204 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-06-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00451204-2016-06-16-4a9caad1c155`](#source-ctg-observation-nct00451204-2016-06-16-4a9caad1c155))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00451204 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-06-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00451204-2016-06-16-4a9caad1c155`](#source-ctg-observation-nct00451204-2016-06-16-4a9caad1c155))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00451204-2016-06-16-4a9caad1c155`](#source-ctg-observation-nct00451204-2016-06-16-4a9caad1c155))

### Sources

<a id="source-ctg-observation-nct00451204-2016-06-16-4a9caad1c155"></a>
- **ClinicalTrials.gov record NCT00451204 · retained source version 2016-06-16:4a9caad1c15591f83307ec39ddedca3a5885c7524b80b87d69c91a4c54eb8c39** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00451204) (`ctg-observation-nct00451204-2016-06-16-4a9caad1c155`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00451204." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00451204-glatiramer-acetate-v1 SHA-256: 2341e75e5bf8b471c8cbabd975314b3113cca71dce36211d28f222a1cac3ec4a.

---

<a id="clinicaltrials-gov-nct00451451-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00451451

> PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00451451-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-01-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00451451-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00451451-glatiramer-acetate-v1
- Content SHA-256: `3529a3b6d0645e9d90bd4461ba8b4d00b5cc69fc14f1b5b45af30a384d7df9d1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00451451 ([`ctg-observation-nct00451451-2015-01-26-533996464e2e`](#source-ctg-observation-nct00451451-2015-01-26-533996464e2e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00451451-2015-01-26-533996464e2e`](#source-ctg-observation-nct00451451-2015-01-26-533996464e2e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00451451-2015-01-26-533996464e2e`](#source-ctg-observation-nct00451451-2015-01-26-533996464e2e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00451451-2015-01-26-533996464e2e`](#source-ctg-observation-nct00451451-2015-01-26-533996464e2e))

### Sources

<a id="source-ctg-observation-nct00451451-2015-01-26-533996464e2e"></a>
- **ClinicalTrials.gov record NCT00451451 · retained source version 2015-01-26:533996464e2ede047a3696ba30b862bf4ac3df847ef6fdff19fb91de77affad4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00451451) (`ctg-observation-nct00451451-2015-01-26-533996464e2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00451451." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00451451-glatiramer-acetate-v1 SHA-256: 3529a3b6d0645e9d90bd4461ba8b4d00b5cc69fc14f1b5b45af30a384d7df9d1.

---

<a id="clinicaltrials-gov-nct00475865-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00475865

> PeptideScanner retained ClinicalTrials.gov record NCT00475865 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-11-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00475865-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-11-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00475865-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00475865-glatiramer-acetate-v1
- Content SHA-256: `4208a65640940e08d171e2153e32cf91e4e92c284b4f993a4cf3561a8ee3aab3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00475865 ([`ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda`](#source-ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00475865 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-11-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda`](#source-ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00475865 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-11-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda`](#source-ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda`](#source-ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda))

### Sources

<a id="source-ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda"></a>
- **ClinicalTrials.gov record NCT00475865 · retained source version 2012-11-06:3b6cdcf04dda72ee0f4989022ca4462333e0a5313d455da447b27803f790b575** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00475865) (`ctg-observation-nct00475865-2012-11-06-3b6cdcf04dda`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00475865." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00475865-glatiramer-acetate-v1 SHA-256: 4208a65640940e08d171e2153e32cf91e4e92c284b4f993a4cf3561a8ee3aab3.

---

<a id="clinicaltrials-gov-nct00666224-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00666224

> PeptideScanner retained ClinicalTrials.gov record NCT00666224 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-06-25, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00666224-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-06-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00666224-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00666224-glatiramer-acetate-v1
- Content SHA-256: `1ea80ddf788d2f501575d26172b56ac82f207590bee32c8c710e95631fdc8341`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00666224 ([`ctg-observation-nct00666224-2012-06-25-7a508c86625a`](#source-ctg-observation-nct00666224-2012-06-25-7a508c86625a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00666224 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-06-25, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00666224-2012-06-25-7a508c86625a`](#source-ctg-observation-nct00666224-2012-06-25-7a508c86625a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00666224 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-06-25, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00666224-2012-06-25-7a508c86625a`](#source-ctg-observation-nct00666224-2012-06-25-7a508c86625a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00666224-2012-06-25-7a508c86625a`](#source-ctg-observation-nct00666224-2012-06-25-7a508c86625a))

### Sources

<a id="source-ctg-observation-nct00666224-2012-06-25-7a508c86625a"></a>
- **ClinicalTrials.gov record NCT00666224 · retained source version 2012-06-25:7a508c86625a93a4da9bc3d0074a355823268b1f48d7e7180524662d3c7206ff** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00666224) (`ctg-observation-nct00666224-2012-06-25-7a508c86625a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00666224." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00666224-glatiramer-acetate-v1 SHA-256: 1ea80ddf788d2f501575d26172b56ac82f207590bee32c8c710e95631fdc8341.

---

<a id="clinicaltrials-gov-nct00811395-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00811395

> PeptideScanner retained ClinicalTrials.gov record NCT00811395 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-12-31, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00811395-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-12-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00811395-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00811395-glatiramer-acetate-v1
- Content SHA-256: `2eea3afa6c5b24908e250fa49fe31965ae0822e2cd62363833574278b79f267d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00811395 ([`ctg-observation-nct00811395-2012-12-31-5e37ac34527b`](#source-ctg-observation-nct00811395-2012-12-31-5e37ac34527b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00811395 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-12-31, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00811395-2012-12-31-5e37ac34527b`](#source-ctg-observation-nct00811395-2012-12-31-5e37ac34527b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00811395 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-12-31, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00811395-2012-12-31-5e37ac34527b`](#source-ctg-observation-nct00811395-2012-12-31-5e37ac34527b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00811395-2012-12-31-5e37ac34527b`](#source-ctg-observation-nct00811395-2012-12-31-5e37ac34527b))

### Sources

<a id="source-ctg-observation-nct00811395-2012-12-31-5e37ac34527b"></a>
- **ClinicalTrials.gov record NCT00811395 · retained source version 2012-12-31:5e37ac34527b05577e1e12977a29ef3112b14f7ec5a6ebee24bac7cba3ccf59b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00811395) (`ctg-observation-nct00811395-2012-12-31-5e37ac34527b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00811395." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00811395-glatiramer-acetate-v1 SHA-256: 2eea3afa6c5b24908e250fa49fe31965ae0822e2cd62363833574278b79f267d.

---

<a id="clinicaltrials-gov-nct00856635-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00856635

> PeptideScanner retained ClinicalTrials.gov record NCT00856635 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00856635-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00856635-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00856635-glatiramer-acetate-v1
- Content SHA-256: `62cbef92769d4fef364091d2850312128146814a2f660988c41e115682a29231`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00856635 ([`ctg-observation-nct00856635-2018-02-06-18b22b8450d4`](#source-ctg-observation-nct00856635-2018-02-06-18b22b8450d4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00856635 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00856635-2018-02-06-18b22b8450d4`](#source-ctg-observation-nct00856635-2018-02-06-18b22b8450d4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00856635 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00856635-2018-02-06-18b22b8450d4`](#source-ctg-observation-nct00856635-2018-02-06-18b22b8450d4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00856635-2018-02-06-18b22b8450d4`](#source-ctg-observation-nct00856635-2018-02-06-18b22b8450d4))

### Sources

<a id="source-ctg-observation-nct00856635-2018-02-06-18b22b8450d4"></a>
- **ClinicalTrials.gov record NCT00856635 · retained source version 2018-02-06:18b22b8450d421cf761ed2fe87b5706e7f87f5171c7d1e99bbc06443af17dd6c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00856635) (`ctg-observation-nct00856635-2018-02-06-18b22b8450d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00856635." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00856635-glatiramer-acetate-v1 SHA-256: 62cbef92769d4fef364091d2850312128146814a2f660988c41e115682a29231.

---

<a id="clinicaltrials-gov-nct00937157-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00937157

> PeptideScanner retained ClinicalTrials.gov record NCT00937157 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-03-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00937157-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-03-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00937157-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00937157-glatiramer-acetate-v1
- Content SHA-256: `41a1fbfdc641bbe1cf227dde92a3981c52282304fb09002177e4af05e1c282d7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00937157 ([`ctg-observation-nct00937157-2021-03-19-8fa77495cd54`](#source-ctg-observation-nct00937157-2021-03-19-8fa77495cd54))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00937157 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-03-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00937157-2021-03-19-8fa77495cd54`](#source-ctg-observation-nct00937157-2021-03-19-8fa77495cd54))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00937157 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-03-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00937157-2021-03-19-8fa77495cd54`](#source-ctg-observation-nct00937157-2021-03-19-8fa77495cd54))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00937157-2021-03-19-8fa77495cd54`](#source-ctg-observation-nct00937157-2021-03-19-8fa77495cd54))

### Sources

<a id="source-ctg-observation-nct00937157-2021-03-19-8fa77495cd54"></a>
- **ClinicalTrials.gov record NCT00937157 · retained source version 2021-03-19:8fa77495cd54d01338cddd05556db51b793aff9d4ea5f646d897a4420a5d2504** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00937157) (`ctg-observation-nct00937157-2021-03-19-8fa77495cd54`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00937157." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00937157-glatiramer-acetate-v1 SHA-256: 41a1fbfdc641bbe1cf227dde92a3981c52282304fb09002177e4af05e1c282d7.

---

<a id="clinicaltrials-gov-nct00947752-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT00947752

> PeptideScanner retained ClinicalTrials.gov record NCT00947752 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-03-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct00947752-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-03-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00947752-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00947752-glatiramer-acetate-v1
- Content SHA-256: `8a23b965e8e3fe9ee8648a2ec902905df925d192a345c0351edff299374b142f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00947752 ([`ctg-observation-nct00947752-2017-03-14-9e884d568e33`](#source-ctg-observation-nct00947752-2017-03-14-9e884d568e33))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00947752 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-03-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00947752-2017-03-14-9e884d568e33`](#source-ctg-observation-nct00947752-2017-03-14-9e884d568e33))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00947752 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-03-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct00947752-2017-03-14-9e884d568e33`](#source-ctg-observation-nct00947752-2017-03-14-9e884d568e33))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00947752-2017-03-14-9e884d568e33`](#source-ctg-observation-nct00947752-2017-03-14-9e884d568e33))

### Sources

<a id="source-ctg-observation-nct00947752-2017-03-14-9e884d568e33"></a>
- **ClinicalTrials.gov record NCT00947752 · retained source version 2017-03-14:9e884d568e331d0fe258036c03b69532df5d1d5030dc625adfb8e5dce44f6445** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00947752) (`ctg-observation-nct00947752-2017-03-14-9e884d568e33`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00947752." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct00947752-glatiramer-acetate-v1 SHA-256: 8a23b965e8e3fe9ee8648a2ec902905df925d192a345c0351edff299374b142f.

---

<a id="clinicaltrials-gov-nct01067521-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT01067521

> PeptideScanner retained ClinicalTrials.gov record NCT01067521 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct01067521-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-12-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01067521-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01067521-glatiramer-acetate-v1
- Content SHA-256: `0438eeaaca1052a2a0503d8b5db97bc4ef2ff89116a19640fda506c11db88442`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01067521 ([`ctg-observation-nct01067521-2021-12-09-68d88d53958a`](#source-ctg-observation-nct01067521-2021-12-09-68d88d53958a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01067521 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01067521-2021-12-09-68d88d53958a`](#source-ctg-observation-nct01067521-2021-12-09-68d88d53958a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01067521 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01067521-2021-12-09-68d88d53958a`](#source-ctg-observation-nct01067521-2021-12-09-68d88d53958a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01067521-2021-12-09-68d88d53958a`](#source-ctg-observation-nct01067521-2021-12-09-68d88d53958a))

### Sources

<a id="source-ctg-observation-nct01067521-2021-12-09-68d88d53958a"></a>
- **ClinicalTrials.gov record NCT01067521 · retained source version 2021-12-09:68d88d53958aaade211d5b1e7683feb43b5b7c98bbcc6cec18f2a1876caa9d87** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01067521) (`ctg-observation-nct01067521-2021-12-09-68d88d53958a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01067521." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01067521-glatiramer-acetate-v1 SHA-256: 0438eeaaca1052a2a0503d8b5db97bc4ef2ff89116a19640fda506c11db88442.

---

<a id="clinicaltrials-gov-nct01071083-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT01071083

> PeptideScanner retained ClinicalTrials.gov record NCT01071083 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-09-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct01071083-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-09-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01071083-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01071083-glatiramer-acetate-v1
- Content SHA-256: `e43628f93b6f97c580945000de7e9bf036ee5913823023e6fba3bbfbf52e78fd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01071083 ([`ctg-observation-nct01071083-2013-09-19-055d7125ba92`](#source-ctg-observation-nct01071083-2013-09-19-055d7125ba92))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01071083 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-09-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01071083-2013-09-19-055d7125ba92`](#source-ctg-observation-nct01071083-2013-09-19-055d7125ba92))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01071083 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-09-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01071083-2013-09-19-055d7125ba92`](#source-ctg-observation-nct01071083-2013-09-19-055d7125ba92))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01071083-2013-09-19-055d7125ba92`](#source-ctg-observation-nct01071083-2013-09-19-055d7125ba92))

### Sources

<a id="source-ctg-observation-nct01071083-2013-09-19-055d7125ba92"></a>
- **ClinicalTrials.gov record NCT01071083 · retained source version 2013-09-19:055d7125ba920d3ad21826a5e97314a650fbc260349fc7f900623598baeb6080** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01071083) (`ctg-observation-nct01071083-2013-09-19-055d7125ba92`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01071083." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01071083-glatiramer-acetate-v1 SHA-256: e43628f93b6f97c580945000de7e9bf036ee5913823023e6fba3bbfbf52e78fd.

---

<a id="clinicaltrials-gov-nct01167426-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT01167426

> PeptideScanner retained ClinicalTrials.gov record NCT01167426 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-10-17, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct01167426-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-10-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01167426-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01167426-glatiramer-acetate-v1
- Content SHA-256: `22ed5b881333893d17e6090d486cb9fbc237b11be94422e5ce33bd87b9a5ba73`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01167426 ([`ctg-observation-nct01167426-2013-10-17-227823edf64d`](#source-ctg-observation-nct01167426-2013-10-17-227823edf64d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01167426 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-10-17, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01167426-2013-10-17-227823edf64d`](#source-ctg-observation-nct01167426-2013-10-17-227823edf64d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01167426 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-10-17, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01167426-2013-10-17-227823edf64d`](#source-ctg-observation-nct01167426-2013-10-17-227823edf64d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01167426-2013-10-17-227823edf64d`](#source-ctg-observation-nct01167426-2013-10-17-227823edf64d))

### Sources

<a id="source-ctg-observation-nct01167426-2013-10-17-227823edf64d"></a>
- **ClinicalTrials.gov record NCT01167426 · retained source version 2013-10-17:227823edf64db81c07069be9fd11e18ad5e4124b320e384561d34b3067332d5b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01167426) (`ctg-observation-nct01167426-2013-10-17-227823edf64d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01167426." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01167426-glatiramer-acetate-v1 SHA-256: 22ed5b881333893d17e6090d486cb9fbc237b11be94422e5ce33bd87b9a5ba73.

---

<a id="clinicaltrials-gov-nct01216072-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT01216072

> PeptideScanner retained ClinicalTrials.gov record NCT01216072 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-02-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct01216072-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-02-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01216072-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01216072-glatiramer-acetate-v1
- Content SHA-256: `25ce8459e53b2ae23d0ce6229058956d44bf81c7c2dec138e1138c99f597f55a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01216072 ([`ctg-observation-nct01216072-2014-02-10-dfb343034e5f`](#source-ctg-observation-nct01216072-2014-02-10-dfb343034e5f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01216072 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-02-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01216072-2014-02-10-dfb343034e5f`](#source-ctg-observation-nct01216072-2014-02-10-dfb343034e5f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01216072 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-02-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01216072-2014-02-10-dfb343034e5f`](#source-ctg-observation-nct01216072-2014-02-10-dfb343034e5f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01216072-2014-02-10-dfb343034e5f`](#source-ctg-observation-nct01216072-2014-02-10-dfb343034e5f))

### Sources

<a id="source-ctg-observation-nct01216072-2014-02-10-dfb343034e5f"></a>
- **ClinicalTrials.gov record NCT01216072 · retained source version 2014-02-10:dfb343034e5f47764acc1f20b07a4a7b44135ab3dfd664b6c0faf61b7e59c8f9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01216072) (`ctg-observation-nct01216072-2014-02-10-dfb343034e5f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01216072." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01216072-glatiramer-acetate-v1 SHA-256: 25ce8459e53b2ae23d0ce6229058956d44bf81c7c2dec138e1138c99f597f55a.

---

<a id="clinicaltrials-gov-nct01317004-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT01317004

> PeptideScanner retained ClinicalTrials.gov record NCT01317004 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-06-22, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct01317004-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-06-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01317004-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01317004-glatiramer-acetate-v1
- Content SHA-256: `1c1e833f1db66483a7718df7cb1dd59a756165609cc3a5f9817a2ff1e3af9510`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01317004 ([`ctg-observation-nct01317004-2015-06-22-59fd74d9890f`](#source-ctg-observation-nct01317004-2015-06-22-59fd74d9890f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01317004 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-06-22, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01317004-2015-06-22-59fd74d9890f`](#source-ctg-observation-nct01317004-2015-06-22-59fd74d9890f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01317004 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-06-22, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01317004-2015-06-22-59fd74d9890f`](#source-ctg-observation-nct01317004-2015-06-22-59fd74d9890f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01317004-2015-06-22-59fd74d9890f`](#source-ctg-observation-nct01317004-2015-06-22-59fd74d9890f))

### Sources

<a id="source-ctg-observation-nct01317004-2015-06-22-59fd74d9890f"></a>
- **ClinicalTrials.gov record NCT01317004 · retained source version 2015-06-22:59fd74d9890f52ca648c6f96b80948bbe9c51502a7c9e1dc479d1391860d9e61** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01317004) (`ctg-observation-nct01317004-2015-06-22-59fd74d9890f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01317004." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01317004-glatiramer-acetate-v1 SHA-256: 1c1e833f1db66483a7718df7cb1dd59a756165609cc3a5f9817a2ff1e3af9510.

---

<a id="clinicaltrials-gov-nct01534182-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT01534182

> PeptideScanner retained ClinicalTrials.gov record NCT01534182 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-08-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct01534182-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-08-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01534182-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01534182-glatiramer-acetate-v1
- Content SHA-256: `f18f22fd0cd105577721640a2dddfd04ba9b0fd41427c873daa21c70d3a23d2a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01534182 ([`ctg-observation-nct01534182-2014-08-08-040232e14ca3`](#source-ctg-observation-nct01534182-2014-08-08-040232e14ca3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01534182 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-08-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01534182-2014-08-08-040232e14ca3`](#source-ctg-observation-nct01534182-2014-08-08-040232e14ca3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01534182 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-08-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01534182-2014-08-08-040232e14ca3`](#source-ctg-observation-nct01534182-2014-08-08-040232e14ca3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01534182-2014-08-08-040232e14ca3`](#source-ctg-observation-nct01534182-2014-08-08-040232e14ca3))

### Sources

<a id="source-ctg-observation-nct01534182-2014-08-08-040232e14ca3"></a>
- **ClinicalTrials.gov record NCT01534182 · retained source version 2014-08-08:040232e14ca34f58613e613b3d35fc686a18162d08308967801ce0031e5f1cb0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01534182) (`ctg-observation-nct01534182-2014-08-08-040232e14ca3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01534182." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01534182-glatiramer-acetate-v1 SHA-256: f18f22fd0cd105577721640a2dddfd04ba9b0fd41427c873daa21c70d3a23d2a.

---

<a id="clinicaltrials-gov-nct01569451-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT01569451

> PeptideScanner retained ClinicalTrials.gov record NCT01569451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct01569451-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-06-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01569451-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01569451-glatiramer-acetate-v1
- Content SHA-256: `9825f16ba33cc9ce5e2eb21ff06557ed554cc102bca7f688d0c5bfaa6107e64c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01569451 ([`ctg-observation-nct01569451-2018-06-08-28103b1d97a9`](#source-ctg-observation-nct01569451-2018-06-08-28103b1d97a9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01569451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01569451-2018-06-08-28103b1d97a9`](#source-ctg-observation-nct01569451-2018-06-08-28103b1d97a9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01569451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01569451-2018-06-08-28103b1d97a9`](#source-ctg-observation-nct01569451-2018-06-08-28103b1d97a9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01569451-2018-06-08-28103b1d97a9`](#source-ctg-observation-nct01569451-2018-06-08-28103b1d97a9))

### Sources

<a id="source-ctg-observation-nct01569451-2018-06-08-28103b1d97a9"></a>
- **ClinicalTrials.gov record NCT01569451 · retained source version 2018-06-08:28103b1d97a9e569e4969bb4d92972078f8daf35d9623c83910803087eb99afa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01569451) (`ctg-observation-nct01569451-2018-06-08-28103b1d97a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01569451." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01569451-glatiramer-acetate-v1 SHA-256: 9825f16ba33cc9ce5e2eb21ff06557ed554cc102bca7f688d0c5bfaa6107e64c.

---

<a id="clinicaltrials-gov-nct01874145-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT01874145

> PeptideScanner retained ClinicalTrials.gov record NCT01874145 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-01-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct01874145-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-01-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01874145-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01874145-glatiramer-acetate-v1
- Content SHA-256: `c62924a919d34b84e6cadd98c54aa435d2b1607595586264f401b6ca76ca0c63`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01874145 ([`ctg-observation-nct01874145-2016-01-14-59cd2d242360`](#source-ctg-observation-nct01874145-2016-01-14-59cd2d242360))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01874145 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-01-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01874145-2016-01-14-59cd2d242360`](#source-ctg-observation-nct01874145-2016-01-14-59cd2d242360))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01874145 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-01-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct01874145-2016-01-14-59cd2d242360`](#source-ctg-observation-nct01874145-2016-01-14-59cd2d242360))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01874145-2016-01-14-59cd2d242360`](#source-ctg-observation-nct01874145-2016-01-14-59cd2d242360))

### Sources

<a id="source-ctg-observation-nct01874145-2016-01-14-59cd2d242360"></a>
- **ClinicalTrials.gov record NCT01874145 · retained source version 2016-01-14:59cd2d2423606de2337fdb8d1e4c94c1382f686361dbaa31da9e0c9b098da431** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01874145) (`ctg-observation-nct01874145-2016-01-14-59cd2d242360`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01874145." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct01874145-glatiramer-acetate-v1 SHA-256: c62924a919d34b84e6cadd98c54aa435d2b1607595586264f401b6ca76ca0c63.

---

<a id="clinicaltrials-gov-nct02153723-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT02153723

> PeptideScanner retained ClinicalTrials.gov record NCT02153723 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-11-05, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct02153723-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-11-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02153723-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct02153723-glatiramer-acetate-v1
- Content SHA-256: `55e15c6f962fc0d35469400d66646bb8a0019cc0dba6c616a096ca9785c99881`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02153723 ([`ctg-observation-nct02153723-2018-11-05-5ca74ba81099`](#source-ctg-observation-nct02153723-2018-11-05-5ca74ba81099))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02153723 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-11-05, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct02153723-2018-11-05-5ca74ba81099`](#source-ctg-observation-nct02153723-2018-11-05-5ca74ba81099))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02153723 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-11-05, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct02153723-2018-11-05-5ca74ba81099`](#source-ctg-observation-nct02153723-2018-11-05-5ca74ba81099))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02153723-2018-11-05-5ca74ba81099`](#source-ctg-observation-nct02153723-2018-11-05-5ca74ba81099))

### Sources

<a id="source-ctg-observation-nct02153723-2018-11-05-5ca74ba81099"></a>
- **ClinicalTrials.gov record NCT02153723 · retained source version 2018-11-05:5ca74ba81099f5c9578f7e2a76933a264429dc591fe754be3af7f47d630e39dd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02153723) (`ctg-observation-nct02153723-2018-11-05-5ca74ba81099`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02153723." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct02153723-glatiramer-acetate-v1 SHA-256: 55e15c6f962fc0d35469400d66646bb8a0019cc0dba6c616a096ca9785c99881.

---

<a id="clinicaltrials-gov-nct02499900-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT02499900

> PeptideScanner retained ClinicalTrials.gov record NCT02499900 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct02499900-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-12-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02499900-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct02499900-glatiramer-acetate-v1
- Content SHA-256: `c2c26b40294f76df939708943ee86b0fb643b5ebbe81b56a9defd00b94ecc23c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02499900 ([`ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b`](#source-ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02499900 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b`](#source-ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02499900 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b`](#source-ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b`](#source-ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b))

### Sources

<a id="source-ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b"></a>
- **ClinicalTrials.gov record NCT02499900 · retained source version 2021-12-09:d1cd6b467f5bee392287d3f5ec751cb028cc9a4b77e83a92872a42f868e59c28** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02499900) (`ctg-observation-nct02499900-2021-12-09-d1cd6b467f5b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02499900." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct02499900-glatiramer-acetate-v1 SHA-256: c2c26b40294f76df939708943ee86b0fb643b5ebbe81b56a9defd00b94ecc23c.

---

<a id="clinicaltrials-gov-nct03193866-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT03193866

> PeptideScanner retained ClinicalTrials.gov record NCT03193866 at 2026-11-16T17:42:50.457Z. Its registry update date was 2025-04-20, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct03193866-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03193866-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct03193866-glatiramer-acetate-v1
- Content SHA-256: `4a03cb26a41f0c3ccb93e1ea7aac038c13331fa83db2552b328e4c07043061d7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03193866 ([`ctg-observation-nct03193866-2025-04-20-da231ac970aa`](#source-ctg-observation-nct03193866-2025-04-20-da231ac970aa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03193866 at 2026-11-16T17:42:50.457Z. Its registry update date was 2025-04-20, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct03193866-2025-04-20-da231ac970aa`](#source-ctg-observation-nct03193866-2025-04-20-da231ac970aa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03193866 at 2026-11-16T17:42:50.457Z. Its registry update date was 2025-04-20, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct03193866-2025-04-20-da231ac970aa`](#source-ctg-observation-nct03193866-2025-04-20-da231ac970aa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03193866-2025-04-20-da231ac970aa`](#source-ctg-observation-nct03193866-2025-04-20-da231ac970aa))

### Sources

<a id="source-ctg-observation-nct03193866-2025-04-20-da231ac970aa"></a>
- **ClinicalTrials.gov record NCT03193866 · retained source version 2025-04-20:da231ac970aa7f45d8a73fd1d1d246747b4ddcebfd5362b6036cd616625424e4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03193866) (`ctg-observation-nct03193866-2025-04-20-da231ac970aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03193866." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct03193866-glatiramer-acetate-v1 SHA-256: 4a03cb26a41f0c3ccb93e1ea7aac038c13331fa83db2552b328e4c07043061d7.

---

<a id="clinicaltrials-gov-nct05344469-glatiramer-acetate-v1"></a>

## ClinicalTrials.gov record NCT05344469

> PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

- Evidence object: `story:clinicaltrials-gov-nct05344469-glatiramer-acetate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-16
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05344469-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct05344469-glatiramer-acetate-v1
- Content SHA-256: `31e200eddb37851505c0601ffdc483911fde69dd2676e4dd2ecfd5956f54680b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05344469 ([`ctg-observation-nct05344469-2026-11-16-4df425e304d4`](#source-ctg-observation-nct05344469-2026-11-16-4df425e304d4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct05344469-2026-11-16-4df425e304d4`](#source-ctg-observation-nct05344469-2026-11-16-4df425e304d4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate. ([`ctg-observation-nct05344469-2026-11-16-4df425e304d4`](#source-ctg-observation-nct05344469-2026-11-16-4df425e304d4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05344469-2026-11-16-4df425e304d4`](#source-ctg-observation-nct05344469-2026-11-16-4df425e304d4))

### Sources

<a id="source-ctg-observation-nct05344469-2026-11-16-4df425e304d4"></a>
- **ClinicalTrials.gov record NCT05344469 · retained source version 2026-11-16:4df425e304d4cd3eda46eabb081d4799f7679920d5ce46ab94b3e04d7c5d680a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05344469) (`ctg-observation-nct05344469-2026-11-16-4df425e304d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05344469." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#clinicaltrials-gov-nct05344469-glatiramer-acetate-v1 SHA-256: 31e200eddb37851505c0601ffdc483911fde69dd2676e4dd2ecfd5956f54680b.

---

<a id="fda-drugs-anda090218-v1"></a>

## Drugs@FDA application ANDA090218

> The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda090218:v1`
- Evidence domain: Regulatory
- Date in source: 2015-04-16
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda090218/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda090218-v1
- Content SHA-256: `3f0f6212a6b2b019702c3f0cbc166314a5b4ffcf1598b1f36071cbd197b0c578`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA090218 ([`fda-drugs-anda090218-2015-04-16-d8701eceb9ea`](#source-fda-drugs-anda090218-2015-04-16-d8701eceb9ea))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda090218-2015-04-16-d8701eceb9ea`](#source-fda-drugs-anda090218-2015-04-16-d8701eceb9ea))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda090218-2015-04-16-d8701eceb9ea`](#source-fda-drugs-anda090218-2015-04-16-d8701eceb9ea))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda090218-2015-04-16-d8701eceb9ea`](#source-fda-drugs-anda090218-2015-04-16-d8701eceb9ea))

### Sources

<a id="source-fda-drugs-anda090218-2015-04-16-d8701eceb9ea"></a>
- **Drugs@FDA application ANDA090218 · original submission status AP · 2015-04-16 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090218%22&limit=1) (`fda-drugs-anda090218-2015-04-16-d8701eceb9ea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA090218." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda090218-v1 SHA-256: 3f0f6212a6b2b019702c3f0cbc166314a5b4ffcf1598b1f36071cbd197b0c578.

---

<a id="fda-drugs-anda091646-v1"></a>

## Drugs@FDA application ANDA091646

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091646:v1`
- Evidence domain: Regulatory
- Date in source: 2017-10-03
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091646/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda091646-v1
- Content SHA-256: `095544c859347693dd909466e5cae7d40d987afb2c1e5c37268c27cf5fd3bf80`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091646 ([`fda-drugs-anda091646-2017-10-03-3b5516f07ae2`](#source-fda-drugs-anda091646-2017-10-03-3b5516f07ae2))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda091646-2017-10-03-3b5516f07ae2`](#source-fda-drugs-anda091646-2017-10-03-3b5516f07ae2))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091646 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda091646-2017-10-03-3b5516f07ae2`](#source-fda-drugs-anda091646-2017-10-03-3b5516f07ae2))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091646-2017-10-03-3b5516f07ae2`](#source-fda-drugs-anda091646-2017-10-03-3b5516f07ae2))

### Sources

<a id="source-fda-drugs-anda091646-2017-10-03-3b5516f07ae2"></a>
- **Drugs@FDA application ANDA091646 · original submission status AP · 2017-10-03 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091646%22&limit=1) (`fda-drugs-anda091646-2017-10-03-3b5516f07ae2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091646." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda091646-v1 SHA-256: 095544c859347693dd909466e5cae7d40d987afb2c1e5c37268c27cf5fd3bf80.

---

<a id="fda-drugs-anda203857-v1"></a>

## Drugs@FDA application ANDA203857

> The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda203857:v1`
- Evidence domain: Regulatory
- Date in source: 2024-09-25
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda203857/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda203857-v1
- Content SHA-256: `6e90dae9faeda1a1f98a6002a8447c386e74c69f3d8a3691e1cf85067e626e1f`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA203857 ([`fda-drugs-anda203857-2024-09-25-e01f62614975`](#source-fda-drugs-anda203857-2024-09-25-e01f62614975))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda203857-2024-09-25-e01f62614975`](#source-fda-drugs-anda203857-2024-09-25-e01f62614975))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 203857 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda203857-2024-09-25-e01f62614975`](#source-fda-drugs-anda203857-2024-09-25-e01f62614975))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda203857-2024-09-25-e01f62614975`](#source-fda-drugs-anda203857-2024-09-25-e01f62614975))

### Sources

<a id="source-fda-drugs-anda203857-2024-09-25-e01f62614975"></a>
- **Drugs@FDA application ANDA203857 · original submission status AP · 2024-09-25 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA203857%22&limit=1) (`fda-drugs-anda203857-2024-09-25-e01f62614975`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA203857." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda203857-v1 SHA-256: 6e90dae9faeda1a1f98a6002a8447c386e74c69f3d8a3691e1cf85067e626e1f.

---

<a id="fda-drugs-anda206873-v1"></a>

## Drugs@FDA application ANDA206873

> The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda206873:v1`
- Evidence domain: Regulatory
- Date in source: 2024-09-25
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda206873/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda206873-v1
- Content SHA-256: `59783360799097c93f9ef42a2d5cf3849cbdf82ab944fd52ed363ad69fec9efd`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA206873 ([`fda-drugs-anda206873-2024-09-25-30827f41a121`](#source-fda-drugs-anda206873-2024-09-25-30827f41a121))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda206873-2024-09-25-30827f41a121`](#source-fda-drugs-anda206873-2024-09-25-30827f41a121))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 206873 with status AP dated 2024-09-25, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda206873-2024-09-25-30827f41a121`](#source-fda-drugs-anda206873-2024-09-25-30827f41a121))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda206873-2024-09-25-30827f41a121`](#source-fda-drugs-anda206873-2024-09-25-30827f41a121))

### Sources

<a id="source-fda-drugs-anda206873-2024-09-25-30827f41a121"></a>
- **Drugs@FDA application ANDA206873 · original submission status AP · 2024-09-25 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206873%22&limit=1) (`fda-drugs-anda206873-2024-09-25-30827f41a121`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA206873." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda206873-v1 SHA-256: 59783360799097c93f9ef42a2d5cf3849cbdf82ab944fd52ed363ad69fec9efd.

---

<a id="fda-drugs-anda206921-v1"></a>

## Drugs@FDA application ANDA206921

> The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda206921:v1`
- Evidence domain: Regulatory
- Date in source: 2018-02-12
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda206921/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda206921-v1
- Content SHA-256: `250499ef3356e7c7130654d92608f8ef31a2d329e0ee7187ea7eb9f040a2f1a2`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA206921 ([`fda-drugs-anda206921-2018-02-12-014b24a224cc`](#source-fda-drugs-anda206921-2018-02-12-014b24a224cc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda206921-2018-02-12-014b24a224cc`](#source-fda-drugs-anda206921-2018-02-12-014b24a224cc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 206921 with status AP dated 2018-02-12, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda206921-2018-02-12-014b24a224cc`](#source-fda-drugs-anda206921-2018-02-12-014b24a224cc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda206921-2018-02-12-014b24a224cc`](#source-fda-drugs-anda206921-2018-02-12-014b24a224cc))

### Sources

<a id="source-fda-drugs-anda206921-2018-02-12-014b24a224cc"></a>
- **Drugs@FDA application ANDA206921 · original submission status AP · 2018-02-12 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206921%22&limit=1) (`fda-drugs-anda206921-2018-02-12-014b24a224cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA206921." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda206921-v1 SHA-256: 250499ef3356e7c7130654d92608f8ef31a2d329e0ee7187ea7eb9f040a2f1a2.

---

<a id="fda-drugs-anda206936-v1"></a>

## Drugs@FDA application ANDA206936

> The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda206936:v1`
- Evidence domain: Regulatory
- Date in source: 2017-10-03
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda206936/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda206936-v1
- Content SHA-256: `fd3acc72cfbf5c1eca9150d4340cc85002d2fd1d5a22c9f57bc7101ca58d78ad`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA206936 ([`fda-drugs-anda206936-2017-10-03-ebebd5ddb710`](#source-fda-drugs-anda206936-2017-10-03-ebebd5ddb710))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda206936-2017-10-03-ebebd5ddb710`](#source-fda-drugs-anda206936-2017-10-03-ebebd5ddb710))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 206936 with status AP dated 2017-10-03, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda206936-2017-10-03-ebebd5ddb710`](#source-fda-drugs-anda206936-2017-10-03-ebebd5ddb710))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda206936-2017-10-03-ebebd5ddb710`](#source-fda-drugs-anda206936-2017-10-03-ebebd5ddb710))

### Sources

<a id="source-fda-drugs-anda206936-2017-10-03-ebebd5ddb710"></a>
- **Drugs@FDA application ANDA206936 · original submission status AP · 2017-10-03 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206936%22&limit=1) (`fda-drugs-anda206936-2017-10-03-ebebd5ddb710`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA206936." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda206936-v1 SHA-256: fd3acc72cfbf5c1eca9150d4340cc85002d2fd1d5a22c9f57bc7101ca58d78ad.

---

<a id="fda-drugs-anda208468-v1"></a>

## Drugs@FDA application ANDA208468

> The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda208468:v1`
- Evidence domain: Regulatory
- Date in source: 2025-05-07
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda208468/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda208468-v1
- Content SHA-256: `573f0f88aedfa9bd82f893301861cf8487cfaa01edecd16f479d460547096173`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA208468 ([`fda-drugs-anda208468-2025-05-07-bda2784275a3`](#source-fda-drugs-anda208468-2025-05-07-bda2784275a3))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda208468-2025-05-07-bda2784275a3`](#source-fda-drugs-anda208468-2025-05-07-bda2784275a3))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda208468-2025-05-07-bda2784275a3`](#source-fda-drugs-anda208468-2025-05-07-bda2784275a3))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda208468-2025-05-07-bda2784275a3`](#source-fda-drugs-anda208468-2025-05-07-bda2784275a3))

### Sources

<a id="source-fda-drugs-anda208468-2025-05-07-bda2784275a3"></a>
- **Drugs@FDA application ANDA208468 · original submission status AP · 2025-05-07 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA208468%22&limit=1) (`fda-drugs-anda208468-2025-05-07-bda2784275a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA208468." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda208468-v1 SHA-256: 573f0f88aedfa9bd82f893301861cf8487cfaa01edecd16f479d460547096173.

---

<a id="fda-drugs-anda213382-v1"></a>

## Drugs@FDA application ANDA213382

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213382:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-11
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213382/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda213382-v1
- Content SHA-256: `6bc5136c69690b171f58b53ee422ad52d3ac9377f55319a7d51f25fd62c2c7a7`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213382 ([`fda-drugs-anda213382-2026-02-11-badd05dfc99e`](#source-fda-drugs-anda213382-2026-02-11-badd05dfc99e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda213382-2026-02-11-badd05dfc99e`](#source-fda-drugs-anda213382-2026-02-11-badd05dfc99e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda213382-2026-02-11-badd05dfc99e`](#source-fda-drugs-anda213382-2026-02-11-badd05dfc99e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213382-2026-02-11-badd05dfc99e`](#source-fda-drugs-anda213382-2026-02-11-badd05dfc99e))

### Sources

<a id="source-fda-drugs-anda213382-2026-02-11-badd05dfc99e"></a>
- **Drugs@FDA application ANDA213382 · original submission status AP · 2026-02-11 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213382%22&limit=1) (`fda-drugs-anda213382-2026-02-11-badd05dfc99e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213382." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda213382-v1 SHA-256: 6bc5136c69690b171f58b53ee422ad52d3ac9377f55319a7d51f25fd62c2c7a7.

---

<a id="fda-drugs-anda214022-v1"></a>

## Drugs@FDA application ANDA214022

> The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda214022:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-11
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda214022/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda214022-v1
- Content SHA-256: `7940f7b7a08208c11a478a60426b680bf7c4b0a708ab65ed3ecd9c1316b2717a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA214022 ([`fda-drugs-anda214022-2026-02-11-778629c20662`](#source-fda-drugs-anda214022-2026-02-11-778629c20662))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda214022-2026-02-11-778629c20662`](#source-fda-drugs-anda214022-2026-02-11-778629c20662))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda214022-2026-02-11-778629c20662`](#source-fda-drugs-anda214022-2026-02-11-778629c20662))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda214022-2026-02-11-778629c20662`](#source-fda-drugs-anda214022-2026-02-11-778629c20662))

### Sources

<a id="source-fda-drugs-anda214022-2026-02-11-778629c20662"></a>
- **Drugs@FDA application ANDA214022 · original submission status AP · 2026-02-11 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA214022%22&limit=1) (`fda-drugs-anda214022-2026-02-11-778629c20662`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA214022." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda214022-v1 SHA-256: 7940f7b7a08208c11a478a60426b680bf7c4b0a708ab65ed3ecd9c1316b2717a.

---

<a id="fda-drugs-anda214741-v1"></a>

## Drugs@FDA application ANDA214741

> The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda214741:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-31
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda214741/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda214741-v1
- Content SHA-256: `532b7c6c9226473d0479f5f7b014fc6f0ccf997a448c7fb9ea632b0cf04f97e4`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA214741 ([`fda-drugs-anda214741-2025-12-31-b822a6ada218`](#source-fda-drugs-anda214741-2025-12-31-b822a6ada218))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda214741-2025-12-31-b822a6ada218`](#source-fda-drugs-anda214741-2025-12-31-b822a6ada218))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-anda214741-2025-12-31-b822a6ada218`](#source-fda-drugs-anda214741-2025-12-31-b822a6ada218))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda214741-2025-12-31-b822a6ada218`](#source-fda-drugs-anda214741-2025-12-31-b822a6ada218))

### Sources

<a id="source-fda-drugs-anda214741-2025-12-31-b822a6ada218"></a>
- **Drugs@FDA application ANDA214741 · original submission status AP · 2025-12-31 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA214741%22&limit=1) (`fda-drugs-anda214741-2025-12-31-b822a6ada218`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA214741." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-anda214741-v1 SHA-256: 532b7c6c9226473d0479f5f7b014fc6f0ccf997a448c7fb9ea632b0cf04f97e4.

---

<a id="fda-drugs-nda020622-v1"></a>

## Drugs@FDA application NDA020622

> The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020622:v1`
- Evidence domain: Regulatory
- Date in source: 1996-12-20
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020622/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-nda020622-v1
- Content SHA-256: `996d2f0b52bc0bbc6cd6c39384f3781288910ea4a0abc33e12f514dee9c82520`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020622 ([`fda-drugs-nda020622-1996-12-20-8b38ef3f7173`](#source-fda-drugs-nda020622-1996-12-20-8b38ef3f7173))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-nda020622-1996-12-20-8b38ef3f7173`](#source-fda-drugs-nda020622-1996-12-20-8b38ef3f7173))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020622 with status AP dated 1996-12-20, and names glatiramer acetate among the application record's active ingredients. ([`fda-drugs-nda020622-1996-12-20-8b38ef3f7173`](#source-fda-drugs-nda020622-1996-12-20-8b38ef3f7173))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020622-1996-12-20-8b38ef3f7173`](#source-fda-drugs-nda020622-1996-12-20-8b38ef3f7173))

### Sources

<a id="source-fda-drugs-nda020622-1996-12-20-8b38ef3f7173"></a>
- **Drugs@FDA application NDA020622 · original submission status AP · 1996-12-20 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020622%22&limit=1) (`fda-drugs-nda020622-1996-12-20-8b38ef3f7173`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020622." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#fda-drugs-nda020622-v1 SHA-256: 996d2f0b52bc0bbc6cd6c39384f3781288910ea4a0abc33e12f514dee9c82520.

---

<a id="federal-register-2015-32246-v1"></a>

## Federal Register proposed rule 2015-32246

> The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.

- Evidence object: `story:federal-register-2015-32246:v1`
- Evidence domain: Regulatory
- Date in source: 2015-12-23
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2015-32246/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#federal-register-2015-32246-v1
- Content SHA-256: `c59248ccd44b2a4ff5ae8389a3d92eda75d391c86f96884c4255497ebd3266dd`

### Claims and source pins

#### Headline

Federal Register proposed rule 2015-32246 ([`federal-register-2015-32246-12ad329819b6`](#source-federal-register-2015-32246-12ad329819b6))

#### Summary

The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer. ([`federal-register-2015-32246-12ad329819b6`](#source-federal-register-2015-32246-12ad329819b6))

#### Paragraph 1

The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer. ([`federal-register-2015-32246-12ad329819b6`](#source-federal-register-2015-32246-12ad329819b6))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2015-32246-12ad329819b6`](#source-federal-register-2015-32246-12ad329819b6))

### Sources

<a id="source-federal-register-2015-32246-12ad329819b6"></a>
- **Federal Register proposed rule 2015-32246 · published 2015-12-23 · Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2015-12-23/pdf/2015-32246.pdf) (`federal-register-2015-32246-12ad329819b6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register proposed rule 2015-32246." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#federal-register-2015-32246-v1 SHA-256: c59248ccd44b2a4ff5ae8389a3d92eda75d391c86f96884c4255497ebd3266dd.

---

<a id="federal-register-2016-08682-v1"></a>

## Federal Register notice 2016-08682

> The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.

- Evidence object: `story:federal-register-2016-08682:v1`
- Evidence domain: Regulatory
- Date in source: 2016-04-15
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2016-08682/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#federal-register-2016-08682-v1
- Content SHA-256: `dbebf1252eee75f48888b712e86ed395caab46d1ea47116049fc8bcce5522d88`

### Claims and source pins

#### Headline

Federal Register notice 2016-08682 ([`federal-register-2016-08682-a8a8c9ebf0da`](#source-federal-register-2016-08682-a8a8c9ebf0da))

#### Summary

The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer. ([`federal-register-2016-08682-a8a8c9ebf0da`](#source-federal-register-2016-08682-a8a8c9ebf0da))

#### Paragraph 1

The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer. ([`federal-register-2016-08682-a8a8c9ebf0da`](#source-federal-register-2016-08682-a8a8c9ebf0da))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2016-08682-a8a8c9ebf0da`](#source-federal-register-2016-08682-a8a8c9ebf0da))

### Sources

<a id="source-federal-register-2016-08682-a8a8c9ebf0da"></a>
- **Federal Register notice 2016-08682 · published 2016-04-15 · Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2016-04-15/pdf/2016-08682.pdf) (`federal-register-2016-08682-a8a8c9ebf0da`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2016-08682." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#federal-register-2016-08682-v1 SHA-256: dbebf1252eee75f48888b712e86ed395caab46d1ea47116049fc8bcce5522d88.

---

<a id="federal-register-2018-15735-v1"></a>

## Federal Register notice 2018-15735

> The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.

- Evidence object: `story:federal-register-2018-15735:v1`
- Evidence domain: Regulatory
- Date in source: 2018-07-23
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-15735/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#federal-register-2018-15735-v1
- Content SHA-256: `732ae2af472a413dd766737ba099812816f1e019a1d79dec8b8bbf5c0bce736f`

### Claims and source pins

#### Headline

Federal Register notice 2018-15735 ([`federal-register-2018-15735-0eef766bc979`](#source-federal-register-2018-15735-0eef766bc979))

#### Summary

The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer. ([`federal-register-2018-15735-0eef766bc979`](#source-federal-register-2018-15735-0eef766bc979))

#### Paragraph 1

The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer. ([`federal-register-2018-15735-0eef766bc979`](#source-federal-register-2018-15735-0eef766bc979))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-15735-0eef766bc979`](#source-federal-register-2018-15735-0eef766bc979))

### Sources

<a id="source-federal-register-2018-15735-0eef766bc979"></a>
- **Federal Register notice 2018-15735 · published 2018-07-23 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-07-23/pdf/2018-15735.pdf) (`federal-register-2018-15735-0eef766bc979`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2018-15735." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#federal-register-2018-15735-v1 SHA-256: 732ae2af472a413dd766737ba099812816f1e019a1d79dec8b8bbf5c0bce736f.

---

<a id="pubmed-pmid-22449210-glatiramer-acetate-v1"></a>

## Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

> PubMed lists PMID 22449210 in Expert review of neurotherapeutics as Journal Article, Review, with publication-date metadata of 2012-04 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22449210-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22449210-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-22449210-glatiramer-acetate-v1
- Content SHA-256: `a15b38130430cdd6a7ca1b95dde8d6dd521c51fa6abd46fc05d8f8c873942a0d`

### Claims and source pins

#### Headline

Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. ([`pubmed-observation-pmid-22449210-2015-11-19-42394739cdea`](#source-pubmed-observation-pmid-22449210-2015-11-19-42394739cdea))

#### Summary

PubMed lists PMID 22449210 in Expert review of neurotherapeutics as Journal Article, Review, with publication-date metadata of 2012-04 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22449210-2015-11-19-42394739cdea`](#source-pubmed-observation-pmid-22449210-2015-11-19-42394739cdea))

#### Paragraph 1

PubMed lists PMID 22449210 in Expert review of neurotherapeutics as Journal Article, Review, with publication-date metadata of 2012-04 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22449210-2015-11-19-42394739cdea`](#source-pubmed-observation-pmid-22449210-2015-11-19-42394739cdea))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22449210-2015-11-19-42394739cdea`](#source-pubmed-observation-pmid-22449210-2015-11-19-42394739cdea))

### Sources

<a id="source-pubmed-observation-pmid-22449210-2015-11-19-42394739cdea"></a>
- **Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. · retained source version 1:2015-11-19:current:42394739cdea8f619ff5a7e42727b8750c3e1e19c2297df5619e9f528576a057** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22449210/) (`pubmed-observation-pmid-22449210-2015-11-19-42394739cdea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-22449210-glatiramer-acetate-v1 SHA-256: a15b38130430cdd6a7ca1b95dde8d6dd521c51fa6abd46fc05d8f8c873942a0d.

---

<a id="pubmed-pmid-22989378-glatiramer-acetate-v1"></a>

## TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.

> PubMed lists PMID 22989378 in BMC neurology as Controlled Clinical Trial, Journal Article, with publication-date metadata of 2012-09-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22989378-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22989378-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-22989378-glatiramer-acetate-v1
- Content SHA-256: `54bbe01d636a639c6188d9f03c2c585724965f624acf595c8fdbec833642b3ac`

### Claims and source pins

#### Headline

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. ([`pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620`](#source-pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620))

#### Summary

PubMed lists PMID 22989378 in BMC neurology as Controlled Clinical Trial, Journal Article, with publication-date metadata of 2012-09-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620`](#source-pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620))

#### Paragraph 1

PubMed lists PMID 22989378 in BMC neurology as Controlled Clinical Trial, Journal Article, with publication-date metadata of 2012-09-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620`](#source-pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620`](#source-pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620))

### Sources

<a id="source-pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620"></a>
- **TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. · retained source version 1:2022-04-08:current:ac526e7c36205a0be67504fef8e60e44404f25c3727d789eed7ae493df386845** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22989378/) (`pubmed-observation-pmid-22989378-2022-04-08-ac526e7c3620`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-22989378-glatiramer-acetate-v1 SHA-256: 54bbe01d636a639c6188d9f03c2c585724965f624acf595c8fdbec833642b3ac.

---

<a id="pubmed-pmid-23203082-glatiramer-acetate-v1"></a>

## Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

> PubMed lists PMID 23203082 in International journal of molecular sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-11-09 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23203082-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-05-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23203082-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23203082-glatiramer-acetate-v1
- Content SHA-256: `aacc4ade8bc020097c73bd06b900f9bb2062759fdca8d26eb8da1395fb10b332`

### Claims and source pins

#### Headline

Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? ([`pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a`](#source-pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a))

#### Summary

PubMed lists PMID 23203082 in International journal of molecular sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-11-09 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a`](#source-pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a))

#### Paragraph 1

PubMed lists PMID 23203082 in International journal of molecular sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-11-09 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a`](#source-pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a`](#source-pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a))

### Sources

<a id="source-pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a"></a>
- **Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? · retained source version 1:2024-05-05:current:99c26f644b4a0b7a098f020e97abab6c0d60a443eac4ab7bc5f8291c8072cdfa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23203082/) (`pubmed-observation-pmid-23203082-2024-05-05-99c26f644b4a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23203082-glatiramer-acetate-v1 SHA-256: aacc4ade8bc020097c73bd06b900f9bb2062759fdca8d26eb8da1395fb10b332.

---

<a id="pubmed-pmid-23264098-glatiramer-acetate-v1"></a>

## Interferon beta and glatiramer acetate therapy.

> PubMed lists PMID 23264098 in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2013-01 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23264098-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-02-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23264098-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23264098-glatiramer-acetate-v1
- Content SHA-256: `6b5a210e561f6302960e3c0eb45964069e5c14aaefbf87c0b880cd1c9d3a00b2`

### Claims and source pins

#### Headline

Interferon beta and glatiramer acetate therapy. ([`pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac`](#source-pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac))

#### Summary

PubMed lists PMID 23264098 in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2013-01 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac`](#source-pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac))

#### Paragraph 1

PubMed lists PMID 23264098 in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2013-01 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac`](#source-pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac`](#source-pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac))

### Sources

<a id="source-pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac"></a>
- **Interferon beta and glatiramer acetate therapy. · retained source version 1:2024-02-04:current:44f89c4436ac11461e0f62cdd182a1bf16e727beec3d5e9f236a4398b8066047** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23264098/) (`pubmed-observation-pmid-23264098-2024-02-04-44f89c4436ac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Interferon beta and glatiramer acetate therapy." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23264098-glatiramer-acetate-v1 SHA-256: 6b5a210e561f6302960e3c0eb45964069e5c14aaefbf87c0b880cd1c9d3a00b2.

---

<a id="pubmed-pmid-23424159-glatiramer-acetate-v1"></a>

## Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

> PubMed lists PMID 23424159 in Annals of neurology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-03-11 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23424159-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23424159-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23424159-glatiramer-acetate-v1
- Content SHA-256: `b0e17ff7024859747195a3a9eec15746dc5c94b29ed28d3d5c28ed82f3f748b1`

### Claims and source pins

#### Headline

Randomized study combining interferon and glatiramer acetate in multiple sclerosis. ([`pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22`](#source-pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22))

#### Summary

PubMed lists PMID 23424159 in Annals of neurology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-03-11 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22`](#source-pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22))

#### Paragraph 1

PubMed lists PMID 23424159 in Annals of neurology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-03-11 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22`](#source-pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22`](#source-pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22))

### Sources

<a id="source-pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22"></a>
- **Randomized study combining interferon and glatiramer acetate in multiple sclerosis. · retained source version 1:2026-05-18:current:9be46e239a22a1e6b39a8798d80c0a1bfe00e33a6ff907ba26443806b75aad76** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23424159/) (`pubmed-observation-pmid-23424159-2026-05-18-9be46e239a22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Randomized study combining interferon and glatiramer acetate in multiple sclerosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23424159-glatiramer-acetate-v1 SHA-256: b0e17ff7024859747195a3a9eec15746dc5c94b29ed28d3d5c28ed82f3f748b1.

---

<a id="pubmed-pmid-23589190-glatiramer-acetate-v1"></a>

## Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

> PubMed lists PMID 23589190 in Journal of neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-04-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23589190-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23589190-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23589190-glatiramer-acetate-v1
- Content SHA-256: `a362470f033a60bccf2b27f288e3c70011016e6e98a699fb6f1d7c850a5346c8`

### Claims and source pins

#### Headline

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. ([`pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d`](#source-pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d))

#### Summary

PubMed lists PMID 23589190 in Journal of neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-04-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d`](#source-pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d))

#### Paragraph 1

PubMed lists PMID 23589190 in Journal of neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-04-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d`](#source-pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d`](#source-pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d))

### Sources

<a id="source-pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d"></a>
- **Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. · retained source version 1:2021-10-21:current:c8b9f471581d79f34a2d018e397a07926351d6192dff63a4e4cb8e8939955d00** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23589190/) (`pubmed-observation-pmid-23589190-2021-10-21-c8b9f471581d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Neuroprotection with glatiramer acetate: evidence from the PreCISe trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23589190-glatiramer-acetate-v1 SHA-256: a362470f033a60bccf2b27f288e3c70011016e6e98a699fb6f1d7c850a5346c8.

---

<a id="pubmed-pmid-23709209-glatiramer-acetate-v1"></a>

## The use of interferon Beta and glatiramer acetate in multiple sclerosis.

> PubMed lists PMID 23709209 in Seminars in neurology as Journal Article, Review, with publication-date metadata of 2013-05-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23709209-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23709209-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23709209-glatiramer-acetate-v1
- Content SHA-256: `c980b9171730ae797662032e358d89a3abe9ceec233ab15d575a075a4729729b`

### Claims and source pins

#### Headline

The use of interferon Beta and glatiramer acetate in multiple sclerosis. ([`pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7`](#source-pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7))

#### Summary

PubMed lists PMID 23709209 in Seminars in neurology as Journal Article, Review, with publication-date metadata of 2013-05-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7`](#source-pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7))

#### Paragraph 1

PubMed lists PMID 23709209 in Seminars in neurology as Journal Article, Review, with publication-date metadata of 2013-05-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7`](#source-pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7`](#source-pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7))

### Sources

<a id="source-pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7"></a>
- **The use of interferon Beta and glatiramer acetate in multiple sclerosis. · retained source version 1:2015-11-19:current:6c24bfdfd5e7a7c73055554b6e6e29f064f853cadf7c1f5663c3a69084c2ec08** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23709209/) (`pubmed-observation-pmid-23709209-2015-11-19-6c24bfdfd5e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The use of interferon Beta and glatiramer acetate in multiple sclerosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23709209-glatiramer-acetate-v1 SHA-256: c980b9171730ae797662032e358d89a3abe9ceec233ab15d575a075a4729729b.

---

<a id="pubmed-pmid-23795716-glatiramer-acetate-v1"></a>

## The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.

> PubMed lists PMID 23795716 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2013-06-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23795716-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23795716-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23795716-glatiramer-acetate-v1
- Content SHA-256: `0ce3c5f3ee7be668da5b2a6ce1b03d4ea114e31d3c19bf71eca9793b535c82c9`

### Claims and source pins

#### Headline

The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. ([`pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc`](#source-pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc))

#### Summary

PubMed lists PMID 23795716 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2013-06-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc`](#source-pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc))

#### Paragraph 1

PubMed lists PMID 23795716 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2013-06-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc`](#source-pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc`](#source-pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc))

### Sources

<a id="source-pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc"></a>
- **The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. · retained source version 1:2022-04-08:current:c178f72a73bc193a598632f3cde63a88e52559b2d21c1634a92211caf2609333** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23795716/) (`pubmed-observation-pmid-23795716-2022-04-08-c178f72a73bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-23795716-glatiramer-acetate-v1 SHA-256: 0ce3c5f3ee7be668da5b2a6ce1b03d4ea114e31d3c19bf71eca9793b535c82c9.

---

<a id="pubmed-pmid-25062935-glatiramer-acetate-v1"></a>

## Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

> PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25062935-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25062935-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-25062935-glatiramer-acetate-v1
- Content SHA-256: `af3e87591b440fa27d5ce2f340f537f8446b657c7c6713c8546a1aea6a47c80d`

### Claims and source pins

#### Headline

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. ([`pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a`](#source-pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a))

#### Summary

PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a`](#source-pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a))

#### Paragraph 1

PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a`](#source-pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a`](#source-pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a))

### Sources

<a id="source-pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a"></a>
- **Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. · retained source version 1:2025-07-28:current:b26a79de013ab609bb938f68651c0a376900cd6ed6fa30f1eb4a03fa78ea52ae** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25062935/) (`pubmed-observation-pmid-25062935-2025-07-28-b26a79de013a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-25062935-glatiramer-acetate-v1 SHA-256: af3e87591b440fa27d5ce2f340f537f8446b657c7c6713c8546a1aea6a47c80d.

---

<a id="pubmed-pmid-26445705-glatiramer-acetate-v1"></a>

## Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

> PubMed lists PMID 26445705 in Brain and behavior as Journal Article, Review, with publication-date metadata of 2015-07-14 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26445705-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26445705-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-26445705-glatiramer-acetate-v1
- Content SHA-256: `f08c8f658c5ceb8091e69c6c223a6d3fff1055166b6c97cd7210bcb1208942c0`

### Claims and source pins

#### Headline

Spasticity in multiple sclerosis and role of glatiramer acetate treatment. ([`pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5`](#source-pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5))

#### Summary

PubMed lists PMID 26445705 in Brain and behavior as Journal Article, Review, with publication-date metadata of 2015-07-14 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5`](#source-pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5))

#### Paragraph 1

PubMed lists PMID 26445705 in Brain and behavior as Journal Article, Review, with publication-date metadata of 2015-07-14 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5`](#source-pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5`](#source-pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5))

### Sources

<a id="source-pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5"></a>
- **Spasticity in multiple sclerosis and role of glatiramer acetate treatment. · retained source version 1:2018-11-13:current:b09a87f196d5c9f339a241f7b6d2cc54b42929dcd6ff681566966f01097c1e56** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26445705/) (`pubmed-observation-pmid-26445705-2018-11-13-b09a87f196d5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Spasticity in multiple sclerosis and role of glatiramer acetate treatment." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-26445705-glatiramer-acetate-v1 SHA-256: f08c8f658c5ceb8091e69c6c223a6d3fff1055166b6c97cd7210bcb1208942c0.

---

<a id="pubmed-pmid-26458034-glatiramer-acetate-v1"></a>

## Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.

> PubMed lists PMID 26458034 in JAMA neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-12 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26458034-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-03-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26458034-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-26458034-glatiramer-acetate-v1
- Content SHA-256: `5b630d2b257a2d91e15322287eee94896f03456002cd1915314acc1d310166a7`

### Claims and source pins

#### Headline

Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. ([`pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a`](#source-pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a))

#### Summary

PubMed lists PMID 26458034 in JAMA neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-12 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a`](#source-pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a))

#### Paragraph 1

PubMed lists PMID 26458034 in JAMA neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-12 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a`](#source-pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a`](#source-pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a))

### Sources

<a id="source-pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a"></a>
- **Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. · retained source version 1:2022-03-30:current:ac4cdaa48f9a463ae913fd4bde20e2a959525703d4aff3c958925d56a222ad13** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26458034/) (`pubmed-observation-pmid-26458034-2022-03-30-ac4cdaa48f9a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-26458034-glatiramer-acetate-v1 SHA-256: 5b630d2b257a2d91e15322287eee94896f03456002cd1915314acc1d310166a7.

---

<a id="pubmed-pmid-26671082-glatiramer-acetate-v1"></a>

## Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).

> PubMed lists PMID 26671082 in Journal of the neurological sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-08 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26671082-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-12-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26671082-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-26671082-glatiramer-acetate-v1
- Content SHA-256: `caff6802424c89037db1a3d3864d740a2dd6a2d14ebd1e21a43d9cd2bb2c3768`

### Claims and source pins

#### Headline

Demonstration of equivalence of a generic glatiramer acetate (Glatopa™). ([`pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec`](#source-pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec))

#### Summary

PubMed lists PMID 26671082 in Journal of the neurological sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-08 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec`](#source-pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec))

#### Paragraph 1

PubMed lists PMID 26671082 in Journal of the neurological sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-08 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec`](#source-pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec`](#source-pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec))

### Sources

<a id="source-pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec"></a>
- **Demonstration of equivalence of a generic glatiramer acetate (Glatopa™). · retained source version 1:2015-12-16:current:3b86c1deb4ec802cbed473356bf5d952940a57168b86fccd200e15efbfbef1ea** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26671082/) (`pubmed-observation-pmid-26671082-2015-12-16-3b86c1deb4ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-26671082-glatiramer-acetate-v1 SHA-256: caff6802424c89037db1a3d3864d740a2dd6a2d14ebd1e21a43d9cd2bb2c3768.

---

<a id="pubmed-pmid-27363291-glatiramer-acetate-v1"></a>

## Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate.

> PubMed lists PMID 27363291 in Pediatric neurology as Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-05-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27363291-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-05-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27363291-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-27363291-glatiramer-acetate-v1
- Content SHA-256: `d78eac26f8888c8a35807dd4d891873478b24360b0877e76ddf74204ff992deb`

### Claims and source pins

#### Headline

Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. ([`pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28`](#source-pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28))

#### Summary

PubMed lists PMID 27363291 in Pediatric neurology as Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-05-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28`](#source-pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28))

#### Paragraph 1

PubMed lists PMID 27363291 in Pediatric neurology as Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-05-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28`](#source-pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28`](#source-pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28))

### Sources

<a id="source-pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28"></a>
- **Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. · retained source version 1:2018-05-15:current:9a3f212ecc28149b558a98994c0bfda3cf224ba8587d26268a74bd9a4ec111d0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27363291/) (`pubmed-observation-pmid-27363291-2018-05-15-9a3f212ecc28`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-27363291-glatiramer-acetate-v1 SHA-256: d78eac26f8888c8a35807dd4d891873478b24360b0877e76ddf74204ff992deb.

---

<a id="pubmed-pmid-27473139-glatiramer-acetate-v1"></a>

## MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.

> PubMed lists PMID 27473139 in Neurology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-07-29 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27473139-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27473139-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-27473139-glatiramer-acetate-v1
- Content SHA-256: `b65ec19be76f7e1498c8ddfa5a181581a8a6d802a85ff0f2e3e69adf5513a5b3`

### Claims and source pins

#### Headline

MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. ([`pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140`](#source-pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140))

#### Summary

PubMed lists PMID 27473139 in Neurology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-07-29 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140`](#source-pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140))

#### Paragraph 1

PubMed lists PMID 27473139 in Neurology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-07-29 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140`](#source-pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140`](#source-pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140))

### Sources

<a id="source-pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140"></a>
- **MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b. · retained source version 1:2018-11-13:current:bb82e109d1404824009a4817dd6a203e0919d6eb1c38a475f0f82a3fd0377703** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27473139/) (`pubmed-observation-pmid-27473139-2018-11-13-bb82e109d140`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-27473139-glatiramer-acetate-v1 SHA-256: b65ec19be76f7e1498c8ddfa5a181581a8a6d802a85ff0f2e3e69adf5513a5b3.

---

<a id="pubmed-pmid-27880972-glatiramer-acetate-v1"></a>

## Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

> PubMed lists PMID 27880972 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2016-11-24 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27880972-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27880972-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-27880972-glatiramer-acetate-v1
- Content SHA-256: `9f598cd6bb998f51732330522c6f254b3db13be74d8da254acb5b60cb15e7f92`

### Claims and source pins

#### Headline

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. ([`pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d`](#source-pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d))

#### Summary

PubMed lists PMID 27880972 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2016-11-24 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d`](#source-pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d))

#### Paragraph 1

PubMed lists PMID 27880972 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2016-11-24 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d`](#source-pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d`](#source-pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d))

### Sources

<a id="source-pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d"></a>
- **Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. · retained source version 1:2026-09-06:current:38b98d32077d7c2854a1953da17d18e0034f0699338c2786911b7ae335590105** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27880972/) (`pubmed-observation-pmid-27880972-2026-09-06-38b98d32077d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-27880972-glatiramer-acetate-v1 SHA-256: 9f598cd6bb998f51732330522c6f254b3db13be74d8da254acb5b60cb15e7f92.

---

<a id="pubmed-pmid-29241378-glatiramer-acetate-v1"></a>

## Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.

> PubMed lists PMID 29241378 in Expert opinion on drug delivery as Journal Article, Review, with publication-date metadata of 2017-12-22 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29241378-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29241378-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-29241378-glatiramer-acetate-v1
- Content SHA-256: `968e7889c971b7eb6bd5c25681869d131aae4600d1c918cbe43e8cf001a12618`

### Claims and source pins

#### Headline

Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes. ([`pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22`](#source-pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22))

#### Summary

PubMed lists PMID 29241378 in Expert opinion on drug delivery as Journal Article, Review, with publication-date metadata of 2017-12-22 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22`](#source-pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22))

#### Paragraph 1

PubMed lists PMID 29241378 in Expert opinion on drug delivery as Journal Article, Review, with publication-date metadata of 2017-12-22 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22`](#source-pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22`](#source-pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22))

### Sources

<a id="source-pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22"></a>
- **Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes. · retained source version 1:2019-07-22:current:29dfbf6bff2207009101e96167493ae4303e462a2d421eba09eb2016e7655101** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29241378/) (`pubmed-observation-pmid-29241378-2019-07-22-29dfbf6bff22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-29241378-glatiramer-acetate-v1 SHA-256: 968e7889c971b7eb6bd5c25681869d131aae4600d1c918cbe43e8cf001a12618.

---

<a id="pubmed-pmid-30775037-glatiramer-acetate-v1"></a>

## Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use.

> PubMed lists PMID 30775037 in Multiple sclerosis international as Journal Article, Review, with publication-date metadata of 2019-01-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30775037-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-09-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30775037-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-30775037-glatiramer-acetate-v1
- Content SHA-256: `1533446bbc1f806306c841050238a199e41c663fe43c7494e4c9948f0d56960a`

### Claims and source pins

#### Headline

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. ([`pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6`](#source-pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6))

#### Summary

PubMed lists PMID 30775037 in Multiple sclerosis international as Journal Article, Review, with publication-date metadata of 2019-01-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6`](#source-pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6))

#### Paragraph 1

PubMed lists PMID 30775037 in Multiple sclerosis international as Journal Article, Review, with publication-date metadata of 2019-01-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6`](#source-pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6`](#source-pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6))

### Sources

<a id="source-pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6"></a>
- **Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use. · retained source version 1:2020-09-29:current:ba386bd461c6b1145810ba0439309eff04491ffc7728ed9a4b26bb5709f3ed06** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30775037/) (`pubmed-observation-pmid-30775037-2020-09-29-ba386bd461c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-30775037-glatiramer-acetate-v1 SHA-256: 1533446bbc1f806306c841050238a199e41c663fe43c7494e4c9948f0d56960a.

---

<a id="pubmed-pmid-30902653-glatiramer-acetate-v1"></a>

## Glatiramer acetate: A complex drug beyond biologics.

> PubMed lists PMID 30902653 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, Review, with publication-date metadata of 2019-03-19 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30902653-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-08-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30902653-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-30902653-glatiramer-acetate-v1
- Content SHA-256: `9cea753a035252ec8d4b428df404db9bd72c7b600a22d64cb0dbe7e9d50894e9`

### Claims and source pins

#### Headline

Glatiramer acetate: A complex drug beyond biologics. ([`pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e`](#source-pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e))

#### Summary

PubMed lists PMID 30902653 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, Review, with publication-date metadata of 2019-03-19 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e`](#source-pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e))

#### Paragraph 1

PubMed lists PMID 30902653 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, Review, with publication-date metadata of 2019-03-19 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e`](#source-pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e`](#source-pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e))

### Sources

<a id="source-pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e"></a>
- **Glatiramer acetate: A complex drug beyond biologics. · retained source version 1:2019-08-15:current:99eac34cd41e25faa059d05a6381d377e0452016d0fb3f3bdbf18c0f971f3412** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30902653/) (`pubmed-observation-pmid-30902653-2019-08-15-99eac34cd41e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Glatiramer acetate: A complex drug beyond biologics." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-30902653-glatiramer-acetate-v1 SHA-256: 9cea753a035252ec8d4b428df404db9bd72c7b600a22d64cb0dbe7e9d50894e9.

---

<a id="pubmed-pmid-30905097-glatiramer-acetate-v1"></a>

## Glatiramer Acetate: from Bench to Bed and Back.

> PubMed lists PMID 30905097 in The Israel Medical Association journal : IMAJ as Journal Article, Review, with publication-date metadata of 2019-03 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30905097-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-04-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30905097-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-30905097-glatiramer-acetate-v1
- Content SHA-256: `9126257fb053616b064ca6d258c4df1bc72886e58a0b28c33a775039d4f6177f`

### Claims and source pins

#### Headline

Glatiramer Acetate: from Bench to Bed and Back. ([`pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52`](#source-pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52))

#### Summary

PubMed lists PMID 30905097 in The Israel Medical Association journal : IMAJ as Journal Article, Review, with publication-date metadata of 2019-03 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52`](#source-pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52))

#### Paragraph 1

PubMed lists PMID 30905097 in The Israel Medical Association journal : IMAJ as Journal Article, Review, with publication-date metadata of 2019-03 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52`](#source-pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52`](#source-pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52))

### Sources

<a id="source-pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52"></a>
- **Glatiramer Acetate: from Bench to Bed and Back. · retained source version 1:2019-04-01:current:1314fb9d1f5256072bb1428dc1ddc1b3af0aa16a0a4bf95866034a43e17c53a3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30905097/) (`pubmed-observation-pmid-30905097-2019-04-01-1314fb9d1f52`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Glatiramer Acetate: from Bench to Bed and Back." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-30905097-glatiramer-acetate-v1 SHA-256: 9126257fb053616b064ca6d258c4df1bc72886e58a0b28c33a775039d4f6177f.

---

<a id="pubmed-pmid-31526436-glatiramer-acetate-v1"></a>

## Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate.

> PubMed lists PMID 31526436 in Die Pharmazie as Journal Article, Review, with publication-date metadata of 2019-08-01 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31526436-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-06-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31526436-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-31526436-glatiramer-acetate-v1
- Content SHA-256: `217f2c651f8691d3675922203797a229e9acf27c30204274a535a80e9d1b7215`

### Claims and source pins

#### Headline

Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate. ([`pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d`](#source-pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d))

#### Summary

PubMed lists PMID 31526436 in Die Pharmazie as Journal Article, Review, with publication-date metadata of 2019-08-01 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d`](#source-pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d))

#### Paragraph 1

PubMed lists PMID 31526436 in Die Pharmazie as Journal Article, Review, with publication-date metadata of 2019-08-01 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d`](#source-pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d`](#source-pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d))

### Sources

<a id="source-pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d"></a>
- **Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate. · retained source version 1:2020-06-11:current:9aab94d9010d289fd4f1cbebf97973daa34c06062824c0f15edee2507a18d9b7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31526436/) (`pubmed-observation-pmid-31526436-2020-06-11-9aab94d9010d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-31526436-glatiramer-acetate-v1 SHA-256: 217f2c651f8691d3675922203797a229e9acf27c30204274a535a80e9d1b7215.

---

<a id="pubmed-pmid-32897569-glatiramer-acetate-v1"></a>

## Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial.

> PubMed lists PMID 32897569 in Acta neurologica Scandinavica as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2020-10-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32897569-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-01-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32897569-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-32897569-glatiramer-acetate-v1
- Content SHA-256: `89b456184b9de4a535d5511c5d18e868a511d7d9a84552df3b8d76574d07cfc1`

### Claims and source pins

#### Headline

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial. ([`pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d`](#source-pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d))

#### Summary

PubMed lists PMID 32897569 in Acta neurologica Scandinavica as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2020-10-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d`](#source-pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d))

#### Paragraph 1

PubMed lists PMID 32897569 in Acta neurologica Scandinavica as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2020-10-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d`](#source-pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d`](#source-pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d))

### Sources

<a id="source-pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d"></a>
- **Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial. · retained source version 1:2021-01-19:current:59230b03cf9d6fd27c617083224c724d76cb57f9809f863884d7c3c449e3d67a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32897569/) (`pubmed-observation-pmid-32897569-2021-01-19-59230b03cf9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-32897569-glatiramer-acetate-v1 SHA-256: 89b456184b9de4a535d5511c5d18e868a511d7d9a84552df3b8d76574d07cfc1.

---

<a id="pubmed-pmid-35493825-glatiramer-acetate-v1"></a>

## Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?

> PubMed lists PMID 35493825 in Frontiers in neurology as Journal Article, Review, with publication-date metadata of 2022-04-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35493825-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-07-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35493825-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-35493825-glatiramer-acetate-v1
- Content SHA-256: `206a9e9580806cd9e8e33df5cb58f0e94fa23cd22b0d2b540ed971ae55451373`

### Claims and source pins

#### Headline

Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate? ([`pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34`](#source-pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34))

#### Summary

PubMed lists PMID 35493825 in Frontiers in neurology as Journal Article, Review, with publication-date metadata of 2022-04-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34`](#source-pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34))

#### Paragraph 1

PubMed lists PMID 35493825 in Frontiers in neurology as Journal Article, Review, with publication-date metadata of 2022-04-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34`](#source-pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34`](#source-pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34))

### Sources

<a id="source-pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34"></a>
- **Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate? · retained source version 1:2022-07-16:current:3e20ef3f4f343c2e4d9f2aefc84873863f019a8bb6962245d38553cc70718674** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35493825/) (`pubmed-observation-pmid-35493825-2022-07-16-3e20ef3f4f34`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-35493825-glatiramer-acetate-v1 SHA-256: 206a9e9580806cd9e8e33df5cb58f0e94fa23cd22b0d2b540ed971ae55451373.

---

<a id="pubmed-pmid-35563884-glatiramer-acetate-v1"></a>

## Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.

> PubMed lists PMID 35563884 in Cells as Journal Article, Systematic Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2022-05-07 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35563884-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35563884-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-35563884-glatiramer-acetate-v1
- Content SHA-256: `6aec5a9e4031868d1acede9967f842153856c1cfec523ec10f23826b9dd2342e`

### Claims and source pins

#### Headline

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. ([`pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4`](#source-pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4))

#### Summary

PubMed lists PMID 35563884 in Cells as Journal Article, Systematic Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2022-05-07 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4`](#source-pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4))

#### Paragraph 1

PubMed lists PMID 35563884 in Cells as Journal Article, Systematic Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2022-05-07 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4`](#source-pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4`](#source-pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4))

### Sources

<a id="source-pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4"></a>
- **Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. · retained source version 1:2025-06-23:current:ee0d5b93cce41ee7209b65ba7b4348433bd994785a9f89949c33b30b8ba1d055** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35563884/) (`pubmed-observation-pmid-35563884-2025-06-23-ee0d5b93cce4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-35563884-glatiramer-acetate-v1 SHA-256: 6aec5a9e4031868d1acede9967f842153856c1cfec523ec10f23826b9dd2342e.

---

<a id="pubmed-pmid-39406508-glatiramer-acetate-v1"></a>

## Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair.

> PubMed lists PMID 39406508 in Pharmacological reviews as Journal Article, Review, with publication-date metadata of 2024-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39406508-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39406508-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-39406508-glatiramer-acetate-v1
- Content SHA-256: `c767f4471681d78982de316c1ea4079aaf2de123ef1a724a201590cea83baac1`

### Claims and source pins

#### Headline

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair. ([`pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05`](#source-pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05))

#### Summary

PubMed lists PMID 39406508 in Pharmacological reviews as Journal Article, Review, with publication-date metadata of 2024-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05`](#source-pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05))

#### Paragraph 1

PubMed lists PMID 39406508 in Pharmacological reviews as Journal Article, Review, with publication-date metadata of 2024-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05`](#source-pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05`](#source-pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05))

### Sources

<a id="source-pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05"></a>
- **Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair. · retained source version 1:2026-05-21:current:f1272ae1ef05e177ce7b7592fb14a1af40c6a8d9480e9da48cc6769f477aeb9d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39406508/) (`pubmed-observation-pmid-39406508-2026-05-21-f1272ae1ef05`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-39406508-glatiramer-acetate-v1 SHA-256: c767f4471681d78982de316c1ea4079aaf2de123ef1a724a201590cea83baac1.

---

<a id="pubmed-pmid-41705515-glatiramer-acetate-v1"></a>

## GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.

> PubMed lists PMID 41705515 in Multiple sclerosis (Houndmills, Basingstoke, England) as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41705515-glatiramer-acetate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41705515-glatiramer-acetate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-41705515-glatiramer-acetate-v1
- Content SHA-256: `be4bf913ff33b146d8b3f9ca0613897db07afbbfd6813aea9ceae23d350ce8ab`

### Claims and source pins

#### Headline

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial. ([`pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7`](#source-pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7))

#### Summary

PubMed lists PMID 41705515 in Multiple sclerosis (Houndmills, Basingstoke, England) as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7`](#source-pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7))

#### Paragraph 1

PubMed lists PMID 41705515 in Multiple sclerosis (Houndmills, Basingstoke, England) as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7`](#source-pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7`](#source-pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7))

### Sources

<a id="source-pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7"></a>
- **GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial. · retained source version 1:2026-07-21:current:fbfe72ce76e703fef1f65c8bf824e467b6bc05bd6fc988dcf1775ea45a2093cd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41705515/) (`pubmed-observation-pmid-41705515-2026-07-21-fbfe72ce76e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/glatiramer-acetate.json#pubmed-pmid-41705515-glatiramer-acetate-v1 SHA-256: be4bf913ff33b146d8b3f9ca0613897db07afbbfd6813aea9ceae23d350ce8ab.

